NCT00572078 is a Phase 1 clinical trial of Sorafenib in SOLID TUMORS, sponsored by Safi Shahda.

Who is sponsoring NCT00572078?

NCT00572078 is sponsored by Safi Shahda.

What drugs are being tested in NCT00572078?

Interventions in NCT00572078: Sorafenib.

What condition does NCT00572078 study?

NCT00572078 studies SOLID TUMORS.

Is NCT00572078 still recruiting?

NCT00572078 is currently completed. Last updated 25 September 2017.

Last reviewed 2017-09-25 · How we verify

NCT00572078

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors

Completed Phase 1 Last updated 25 September 2017

What this trial tests

Phase 1 trial testing Sorafenib in SOLID TUMORS in 27 participants. Completed in 14 September 2014.

Timeline

23 January 2008

Primary endpoint
4 January 2011

14 September 2014

Quick facts

Lead sponsor	Safi Shahda
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	23 January 2008
Primary completion	4 January 2011
Estimated completion	14 September 2014
Sites	1 location across United States

Drugs / interventions tested

Sorafenib (SORAFENIB) — full drug profile →

Conditions studied

SOLID TUMORS — all drugs for SOLID TUMORS →

Sponsor

Safi Shahda

Who can join

18 and older, any sex, with SOLID TUMORS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability and describe the maximum tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors.
Chiorean EG, Perkins SM, Strother RM, Younger A, et al · · 2020 · cited 5× · PMID 32847973 · DOI 10.1158/1535-7163.mct-20-0277

Verify or expand the search:

Other trials of Sorafenib

Trials testing the same drug.

NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT06474663 — A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabi · Phase 1 · withdrawn
NCT06690697 — Combination of Toripalimab and JS004 Therapy for ccRCC · Phase 2 · recruiting
NCT06177496 — Influence of Sarcopenia in Hepatocellular Carcinoma Patients · unknown
NCT05033522 — Immunotherapy for Advanced Liver Cancer · Phase 2, PHASE3 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00572078 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Safi Shahda
Last refreshed: 25 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00572078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing